EUVIMEDSkopri EUVIMED
Crossref

Development of IL‐17A inhibitor‐induced atopic dermatitis‐like rash in psoriasis patients: Insights into immune shift

Qiuju Li iD, Xiuying Li, Wenyu Li, Runge Fan, Qing Ma, Xiaomei Luo, Huahui Jian, Xiaozhi Chen, Cunwei Cao, Wenjun Zheng

Experimental Dermatology · 2024

DOI: 10.1111/exd.14958 ↗

At a glance

Journal article in Experimental Dermatology, 2024. Written by Qiuju Li and 9 co-authors. Institution: Department of Dermatology and Venereology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. Major MEDLINE topics: Dermatitis, Atopic, Psoriasis, Exanthema. Cited 9 times so far (Crossref); 19 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Cases of atopic dermatitis (AD)‐like rash induced by IL‐17A inhibitor secukinumab treatment (SI‐AD) have been recently reported in psoriasis patients. To identify immune and inflammatory factors expression in SI‐AD. A panel of 15 immune and inflammatory factors in peripheral blood samples from various groups, including patients with patients with SI‐AD, psoriasis with secukinumab (S‐stable), advanced psoriasis patients (Advanced) and healthy controls (HC). Interleukin‐10 (IL‐10), IL‐4 and IL‐17A were detected in skin tissue biopsy samples by immunohistochemistry and real‐time quantitative polymerase chain reaction. The immunoglobulin E levels in the SI‐AD patients exceeded normal values. The IL‐10 levels in SI‐AD patients were higher than those in S‐stable patients, advanced patients and HC. The IL‐4 levels in SI‐AD patients were higher than that in S‐stable patients and HC. The IL‐17A levels in SI‐AD patients were higher than those in advanced psoriasis patients and HC, but no significant differences were observed between SI‐AD patients and S‐stable patients. IL‐10 and IL‐4 levels were higher in AD‐like rashes than in healthy skin, while IL‐17A did not differ significantly between the two. Upon discontinuing secukinumab, and switching to oral cyclosporine, antihistamines, Janus kinase 1 inhibitor and topical glucocorticoids, SI‐AD patients experienced significant improvement in their skin lesions. Upon reexamination, all 15 immune and inflammatory factors returned to normal levels. Immune shift from Th17 towards Th2 may occur in SI‐AD, as indicated by abnormal expression of multiple immune and inflammatory factors observed in peripheral blood and skin tissues.

Subjects

MeSH terms (MEDLINE)

Dermatitis, AtopicPsoriasisExanthemaHumansInterleukin-10Interleukin-17Interleukin-4

Author keywords

atopic dermatitisimmune and inflammatory factorsimmune shiftpsoriasissecukinumab

Substances

Interleukin-10Interleukin-17Interleukin-4

Authors and institutions

  • Department of Dermatology and Venereology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Department of Dermatology and Venereology, Baise People's Hospital, Baise, China.

ORCID profiles: Qiuju Li

Cite

APA

Li, Q., Li, X., Li, W., Fan, R., Ma, Q., Luo, X., Jian, H., Chen, X., Cao, C., & Zheng, W. (2024). Development of IL‐17A inhibitor‐induced atopic dermatitis‐like rash in psoriasis patients: Insights into immune shift. Experimental Dermatology. https://doi.org/10.1111/exd.14958

Vancouver

Li Q, Li X, Li W, Fan R, Ma Q, Luo X, et al. Development of IL‐17A inhibitor‐induced atopic dermatitis‐like rash in psoriasis patients: Insights into immune shift. Experimental Dermatology. 2024. doi:10.1111/exd.14958

BibTeX
@article{Li2024,
  author = {Li, Qiuju and Li, Xiuying and Li, Wenyu and Fan, Runge and Ma, Qing and Luo, Xiaomei and Jian, Huahui and Chen, Xiaozhi and Cao, Cunwei and Zheng, Wenjun},
  title = {Development of IL‐17A inhibitor‐induced atopic dermatitis‐like rash in psoriasis patients: Insights into immune shift},
  journal = {Experimental Dermatology},
  year = {2024},
  doi = {10.1111/exd.14958}
}
Start for free →